Medical Excellence Capital, LLC

Thank you and Happy Holidays! A short note of appreciation as the year ends. Appreciation for our Investors - MEC‘s reason for being is to advance new medicines that address the most difficult to cure diseases. #ALS, #Parkinson’s, #Children’s #RareDisease, #Cancers - the truly tough ones. We hope that investing wisely in promising, innovative companies will, in turn, provide attractive returns on investment to our investors. MEC investors have literally hundreds of choices of investments offered to them regularly. Some with much lower risk, and some with higher potential returns. So why did they invest in Medical Excellence Capital? Because They Care. Because they want to make a difference. Because they want to be part of an incredible ecosystem that has the potential to materially change the lives of patients and their families. Given the many choices they have in putting their hard earned money to work, the MEC team is grateful they have chosen the ethos of “Doing Well by Doing Good“. Appreciation for our #Biotech Ecosystem - We thank our scientific collaborators, advisors, supporters, like-minded investment syndicate partners, and every single team member of our portfolio companies. We work each day in an amazing, highly-innovative industry that is absolutely critical to individuals suffering from disease. Our industry is also equally critical to our country’s economy and competitive posture. The work being done today by our biotech ecosystem partners will inevitably alleviate the suffering of literally millions of patients throughout the world, while ensuring the U.S. will continue to be the most innovative and attractive hive for biotech innovation. Appreciation for the MEC Team - We began four years ago with a vision to find, invest in, and accelerate innovative companies led by bold scientists and operators. We have literally screened well over 1,300 companies to arrive at making 11 actual investments. This required not only a ton of hard work, but also requires intense debate, time pressures, and collaboration. Teams that have strong personal ties and affinity generally outperform those that do not. We truly look forward to coming to work every day and collaborating to solve the big problems in medicine. Each of are grateful for a most spirited “Esprit de Corps”. Happy holidays in whichever way you celebrate. We have much be thankful for, as a Team, as industry colleagues, and as citizens of this great Nation! The MEC Team John Prufeta, Brian Halak, Eric Heil, Kim Kamdar, Joni Mancini, Max Colbert MD, MBA, Olga Prufeta (Gouroudeva), John P. Hornbostel, Annabel Stoddart, Tess Marvin, Jasmin Revanna

Delighted with the news that Vik Vaz, M.D. will be leading Pleno, an MEC portfolio company. He brings the exact skill set needed for the next phase of Pleno’s commercial development. My partner, Dr. Kim Kamdar, has a stellar reputation and track record in Pleno’s marketplace and will continue to contribute her talents to the Pleno Board of Directors. This announcement is a decided step forward. Congratulations, Vik, and wishing you much success!

We are thrilled to welcome Tina S. Nova, Ph.D., to our Board of Directors! With an extraordinary career advancing cancer diagnostics at Decipher Biosciences (now part of Veracyte), co-founding Genoptix before its acquisition by Novartis, and guiding other companies to successful IPOs and acquisitions, Dr. Nova is a true pioneer in #diagnostics and #biotech. Her expertise in building market-defining businesses will be instrumental as we advance our mission to make #BloodTesting accessible to all. Learn more in our press release: https://lnkd.in/gAGtJdKN

Happy Thanksgiving, dear friends of Medical Excellence Capital! The MEC Team wishes you peace and happiness as we enter the Holiday season. We are grateful for your support and friendship. On a larger scale, we are grateful to be living in a truly great country brimming with innovation, dedicated to moving humanity forward. We are inspired by the dedicated people we work with each day to create the new medicines that relieve human suffering, and proud to be a small part of this circle of supremely talented innovators. The MEC Team gives thanks to you, among our many blessings!

We are thrilled to celebrate 22q Awareness Day together with Nobias Therapeutics and highlight the exciting opportunity for NB-001! The team at Nobias, led by Patrick Dougherty, has focused its resources on its development programs following receipt of positive data from a multi-center, randomized, double blind, placebo-controlled Phase 2 clinical trial of its lead asset, NB-001, for the potential treatment of the neuropsychiatric symptoms associated with 22q11 deletion syndrome (22q11DS), the most common human microdeletion.

Just Released: BENS Member Insights on #Biotechnology's Security Frontier As the biotech sector advances, there is a need for public-private collaboration to stay ahead of potential security risks. In this piece, industry leaders Patrice Bonfiglio, Ansbert Gadicke, M.D., and John Prufeta share their perspectives on managing dual-use advancements, securing #innovation, and more. Dive into their insights on the rapid evolution of biotech and its implications for national security⤵️ https://bit.ly/4fBSEgs #nationalsecurity | #biotech | #supplychains | Sarissa Capital Management LP | MPM Capital | Medical Excellence Capital, LLC

"#Biotechnology is rapidly evolving into a critical arena for #nationalsecurity, with innovations that have profound long-term implications already beginning to emerge. " Business Executives for National Security (BENS) interviewed MEC Founder & General Partner John Prufeta together with Patrice Bonfiglio and Ansbert Gadicke, M.D. highlight several key action items to ensure the secure advancement of biotechnology including: 1. Strengthen #PublicPrivate Partnerships: Enhance collaboration between government agencies and private biotech firms to foster innovation while maintaining robust security measures. 2. Implement Comprehensive #BiosecurityPolicies: Develop and enforce policies that address potential biosecurity threats, ensuring that advancements in biotechnology do not compromise national security. 3. Invest in #WorkforceDevelopment: Allocate resources to train and educate professionals in biotechnology, universities, researchers, and biosecurity, creating a skilled workforce capable of navigating the complexities of the field. 4. Promote #EthicalResearch Practices: Encourage ethical standards in biotech research to prevent misuse and ensure that developments align with societal values and security concerns. 5. Enhance #Domestic Biotechnology Manufacturing: The United States should prioritize domestic production capabilities and reduce reliance on foreign suppliers. 6. Leverage #AdvancedTechnologies: Utilize emerging technologies, such as artificial intelligence and machine learning, to monitor and mitigate biosecurity risks effectively. By focusing on these areas, stakeholders and policymakers can navigate the challenges at the intersection of biotechnology innovation and security, ensuring that advancements benefit society while safeguarding against potential threats. Read the full article here: https://lnkd.in/es-NcUYg

Our company was created to deploy capital that results in the development of great biotech companies. However, we also think of ourselves as citizens of the the industry we serve and the country in which we live. As a result, each of us at MEC volunteer our time to help “make a material difference in the lives of our fellow beings”. Medical Excellence Capital Founder and General Partner John Prufeta recently was interviewed for a thought piece on BioTech and National Security. Please read on…

📰 The MEC Q3 2024 Newsletter went out this week! Read more about MEC's focus on execution, our recent annual meeting, significant progress at our portfolio companies, and exciting science within our MEC Network. Check it out on our MEC Blog page: https://lnkd.in/e47vS3c3 "Execution is the key differentiator between breakthrough success and failure, especially in biotech. As the late Brian Dovey emphasized in his book, 'The Idea is the Easy Part – Myths and Realities of the Startup World', the challenge lies in mastering execution. In life sciences, it is not enough to have a groundbreaking idea—success comes from the ability to adapt, prioritize, and manage the nearly endless complexities of bringing a therapy to market" Click here to subscribe to our newsletter: http://eepurl.com/hSIgP9 #biotech #venturecapital #lifesciences #pharma #startups

📰 The MEC Q3 2024 Newsletter went out this week! Read more about MEC's focus on execution, our recent annual meeting, significant progress at our portfolio companies, and exciting science within our MEC Network. Check it out on our MEC Blog page: https://lnkd.in/e47vS3c3 "Execution is the key differentiator between breakthrough success and failure, especially in biotech. As the late Brian Dovey emphasized in his book, 'The Idea is the Easy Part – Myths and Realities of the Startup World', the challenge lies in mastering execution. In life sciences, it is not enough to have a groundbreaking idea—success comes from the ability to adapt, prioritize, and manage the nearly endless complexities of bringing a therapy to market" Click here to subscribe to our newsletter: http://eepurl.com/hSIgP9 #biotech #venturecapital #lifesciences #pharma #startups